What you'll actually pay
LillyDirect, lowest dose
$149
LillyDirect, highest dose
$349
If your plan covers it
$25/mo
Foundayo is the first oral GLP-1 without food timing restrictions. You can take it with breakfast, lunch, or dinner — the pill works regardless.
Where Foundayo sits
Detailed pricing
Foundayo (orforglipron)
| Option | Cost/Month | Notes |
|---|---|---|
| LillyDirect self-pay | $149–$349/mo | Lower doses cost less; higher doses cost more |
| With insurance | $25/mo | Commercial insurance savings card |
| Medicare Part D (expected) | ~$50/mo | Expected from July 2026 |
Oral medications: cost and convenience
| Option | Cost/Month | Notes |
|---|---|---|
| Foundayo (orforglipron) | $149–$349/mo | Any time, any meal. 12.4% weight loss, ATTAIN-1. |
| Wegovy pill (semaglutide) | $149–$299/mo | Empty stomach only. 16.6% weight loss, OASIS 4. |
| Semaglutide injection | $349–$399/mo | Any time, any meal. 14.9% weight loss, STEP 1. |
| Tirzepatide injection | $299–$449/mo | Any time, any meal. 20.9% weight loss, SURMOUNT-1. |
Insurance coverage reality
Foundayo was FDA approved April 1, 2026 — very new. Insurance companies are still adding it to formularies. Many plans may not yet cover it, or may require prior authorization. Medicare Part D coverage is expected from July 2026 at about $50/month. Medicare does NOT cover for weight loss alone outside that pathway.
How to get the lowest cost
Use LillyDirect for self-pay
Official Eli Lilly programme: $149–$349/mo depending on dose.
No food timing needed
Unlike the Wegovy pill, take Foundayo anytime with any meal. More convenient.
Check your insurance
New drug (April 2026) — coverage ramping up. Check your formulary.
Request coverage if denied
Ask your doctor to request prior authorization for a newly approved drug.
Compare to Wegovy pill
Similar starting price ($149/month for Foundayo vs $149/month for the Wegovy pill), with Foundayo's convenience advantage of no empty-stomach rule.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Price and trial sources for Orforglipron
ATTAIN-1 trial (3,127 adults with obesity, no diabetes) showed 12.4% average weight loss with orforglipron (Foundayo) at the maximum dose. ATTAIN-2 and ATTAIN-MAINTAIN examined tolerability and durability. Pricing per LillyDirect, checked 10 September 2026. Drug approved April 1, 2026.
- ATTAIN-1 — Orforglipron: 3,127 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2025. View source ↗
Keep reading
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: